Miglitol
From Wikipedia, the free encyclopedia
 |
|
|
Miglitol
|
|
| Systematic (IUPAC) name | |
| (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl) piperidine-3,4,5-triol |
|
| Identifiers | |
| CAS number | 72432-03-2 |
| ATC code | A10BF02 |
| PubChem | 441314 |
| DrugBank | APRD01117 |
| Chemical data | |
| Formula | C8H17NO5 |
| Mol. weight | 207.224 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Dose-dependent |
| Protein binding | Negligible (<4.0%) |
| Metabolism | Nil |
| Half life | 2 hours |
| Excretion | Renal (95%) |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. | |
| Legal status |
℞-only(US) |
| Routes | Oral |
Miglitol is an oral anti-diabetic drug that is classified as a alpha-glucosidase inhibitor. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of complex carbohydrates such as starch into sugars which can be absorbed.
Since miglitol works by preventing digestion of complex carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of complex carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
